With Pfizer Inc. pivoting from seeking big M&A deals to grow to investing in internal R&D and smaller, earlier-stage transactions under new CEO Albert Bourla, its gene therapy unit is looking increasingly interesting as a crucible for innovation and potential growth.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?